Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757595

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757595

Frontotemporal Dementia

PUBLISHED:
PAGES: 381 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Frontotemporal Dementia Market to Reach US$366.4 Million by 2030

The global market for Frontotemporal Dementia estimated at US$265.1 Million in the year 2024, is expected to reach US$366.4 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Cognitive Enhancers, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$126.0 Million by the end of the analysis period. Growth in the Antipsychotics segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.2 Million While China is Forecast to Grow at 8.9% CAGR

The Frontotemporal Dementia market in the U.S. is estimated at US$72.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.4 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Frontotemporal Dementia Market - Key Trends & Drivers Summarized

Why Is Frontotemporal Dementia Gaining Increasing Clinical and Research Attention?

Frontotemporal dementia (FTD) is emerging as a critical focus area in neurodegenerative disease research due to its early onset, complex symptomatology, and limited treatment options. Unlike Alzheimer’s disease, which primarily affects memory, FTD leads to significant changes in personality, behavior, and language at an earlier age-typically between 45 and 65 years. As awareness of non-Alzheimer’s dementias rises, clinicians are increasingly recognizing FTD as a distinct diagnostic entity with its own set of pathological subtypes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA).

The growing burden of FTD is prompting urgent calls for better diagnostic frameworks, caregiver support, and disease-modifying therapies. Because FTD is often misdiagnosed as psychiatric illness or late-onset depression, there is a strong push toward biomarker-based tools and imaging diagnostics that can differentiate FTD from other neurological or psychiatric disorders. These developments are creating opportunities for pharmaceutical and diagnostic companies to innovate within this underserved but rapidly expanding disease segment.

How Are Diagnostic and Therapeutic Innovations Transforming Disease Management?

Advancements in neuroimaging, genomics, and molecular pathology are enhancing the diagnostic accuracy and early detection of frontotemporal dementia. PET and MRI imaging techniques are being refined to identify regional brain atrophy, while cerebrospinal fluid (CSF) biomarkers and genetic profiling are enabling differentiation of FTD from Alzheimer's and other neurodegenerative conditions. The emergence of biomarkers such as tau and TDP-43 proteins is opening pathways for precision medicine approaches in FTD care.

On the therapeutic front, research is shifting from symptomatic relief toward disease-modifying targets. Pipeline therapies are exploring mechanisms that address underlying proteinopathies, neuroinflammation, and synaptic dysfunction. RNA-based therapies, antisense oligonucleotides (ASOs), and tau aggregation inhibitors are entering clinical trials, aiming to slow or halt disease progression. In parallel, digital therapeutics and behavioral interventions are being developed to manage the cognitive and emotional symptoms associated with the disease. These innovations are setting the stage for a paradigm shift in how FTD is approached both clinically and commercially.

Which Stakeholders Are Driving the Push for Targeted FTD Solutions?

The ecosystem surrounding frontotemporal dementia is witnessing increased engagement from academic researchers, biotech firms, patient advocacy groups, and health regulators. Rare disease frameworks and orphan drug policies are supporting innovation in this relatively low-prevalence yet high-burden segment. Patient registries and longitudinal observational studies are supplying valuable data to aid in understanding disease progression, facilitating clinical trial design, and identifying early biomarkers.

Pharmaceutical companies are recognizing the unmet medical need in FTD and leveraging their neurodegeneration R&D platforms-often built around Alzheimer’s and Parkinson’s research-to pivot into FTD indications. Venture capital funding and collaborative consortia are also flowing into FTD-focused biotechs aiming to lead in niche neurology. The increasing role of digital diagnostics and remote cognitive assessments is further enabling decentralized patient monitoring, widening access to care for individuals in early-stage or rural settings.

What Are the Primary Drivers Fueling Growth in the Frontotemporal Dementia Market?

The growth in the frontotemporal dementia market is driven by several factors related to diagnostic innovation, clinical research momentum, and the rise of precision neurology. One of the most powerful growth drivers is the increasing recognition of FTD as a distinct and underdiagnosed condition, which is spurring demand for advanced neuroimaging, genetic testing, and AI-based diagnostic platforms. As the prevalence of early-onset dementias rises globally, there is a corresponding need for accurate, timely diagnosis and personalized care pathways.

Another key driver is the surge in pharmaceutical R&D focused on neurodegenerative proteinopathies, especially tauopathies, which overlap with FTD pathogenesis. The availability of orphan drug incentives, fast-track regulatory designations, and growing public-private research partnerships are accelerating the development of FTD-targeted treatments. Additionally, the emotional and economic burden of FTD on working-age populations is prompting payers and policymakers to prioritize early intervention strategies and support services. These intersecting dynamics are positioning the frontotemporal dementia market as a high-impact growth frontier in neurology.

SCOPE OF STUDY:

The report analyzes the Frontotemporal Dementia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Other Drug Classes); Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorders); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Alector Inc.
  • Allergan plc
  • Apotex Inc.
  • Asceneuron SA
  • AstraZeneca plc
  • AviadoBio Ltd.
  • Biogen Inc.
  • CervoMed Inc.
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Passage Bio, Inc.
  • Pfizer Inc.
  • Prevail Therapeutics
  • Sanofi S.A.
  • Wave Life Sciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36943

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Frontotemporal Dementia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Population Propels Demand for Specialized Dementia Treatments
    • Advancements in Genetic Research Enhance Understanding of Disease Mechanisms
    • Increased Awareness and Early Diagnosis Initiatives Drive Market Growth
    • Development of Precision Medicine Strengthens Personalized Treatment Approaches
    • Rising Investment in Neurodegenerative Disease Research Fuels Therapeutic Innovations
    • Integration of AI and Telemedicine Improves Patient Monitoring and Care
    • Emergence of Biomarker-Based Diagnostics Enhances Early Detection Capabilities
    • Growing Demand for Non-Pharmacologic Therapies Supports Market Diversification
    • Implementation of Dementia-Friendly Community Programs Encourages Social Inclusion
    • Expansion of Caregiver Support Services Addresses Increasing Care Demands
    • Adoption of Digital Health Records Improves Data Sharing and Patient Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Frontotemporal Dementia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Cognitive Enhancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for CNS Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Primary Progressive Aphasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Movement Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • JAPAN
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • CHINA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • EUROPE
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • FRANCE
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • GERMANY
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • INDIA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • AFRICA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!